Latest Integral membrane proteins Stories
Scientists from VIB and KU Leuven have discovered a new target molecule for the development of a treatment against Alzheimer's disease. There is currently no cure for this disease. Many candidate drugs fail because they also target proteins essential to life. This discovery from Leuven could form a target for a treatment against Alzheimer's disease with fewer side effects and that suppresses the very first symptoms of the disease. This research will be published in the leading journal Nature...
Alzheimer's disease is one of the most common causes of dementia. In Germany and Switzerland alone, around 1.5 million people are affected, and forecasts predict a doubling of the number of patients worldwide within the next 20 years. The accumulation of particular abnormal proteins, including amyloid-ß (Aβ) among others, in patients' brains plays a central role in this disease. Prof. Frank Heppner from the Department of Neuropathology at Charité and his colleague Prof. Burkhard Becher...
SEATTLE, Nov. 15, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that GPR17-targeting compounds, which were previously identified by Omeros in connection with unlocking this orphan receptor, have now been demonstrated to promote differentiation of the cells that form myelin in the central nervous system. Myelin is critical for the proper functioning of the nervous system, and demyelination is associated with multiple nervous system disorders, including...
PHILADELPHIA and LONDON, Nov. 12, 2012 /PRNewswire/ -- MediciGlobal Inc., announced today that over 25,000 fans have shown their support for clinical research by joining the Facebook page Alzheimer's Team. The community supports research efforts into clinical research aimed at halting the progression of mild to moderate Alzheimer's disease. "We are the first Facebook community to inform people about the role of Tau tangles in Alzheimer's disease, and the development of the first...
Mouse model may provide clues on mechanism linking diabetes and aging to Alzheimer's Growing evidence suggests that there may be a link between diabetes and Alzheimer's disease, but the physiological mechanisms by which diabetes impacts brain function and cognition are not fully understood. In a new study published in Aging Cell, researchers at the Salk Institute for Biological Studies show, for the first time, that diabetes enhances the development of aging features that may underlie...
SEATTLE, Oct. 24, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of four additional orphan G protein-coupled receptors (GPCRs). Without compounds that functionally interact with orphan GPCRs, developing drugs targeting those receptors is extremely difficult. Omeros has now unlocked 46 Class A orphan GPCRs, representing almost 60 percent of these targets and equaling the number of GPCRs...
Researchers at Washington University School of Medicine in St. Louis have found a key difference in the brains of people with Alzheimer's disease and those who are cognitively normal but still have brain plaques that characterize this type of dementia. "There is a very interesting group of people whose thinking and memory are normal, even late in life, yet their brains are full of amyloid beta plaques that appear to be identical to what's seen in Alzheimer's disease," says David L. Brody,...
Chemists at the California Institute of Technology (Caltech) have managed, for the first time, to simulate the biological function of a channel called the Sec translocon, which allows specific proteins to pass through membranes. The feat required bridging timescales from the realm of nanoseconds all the way up to full minutes, exceeding the scope of earlier simulation efforts by more than six orders of magnitude. The result is a detailed molecular understanding of how the translocon works....
CLEVELAND, Sept. 17, 2012 /PRNewswire/ -- ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes. (Logo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO ) "This grant will allow us to optimize our industry-leading cardiomyocyte...
WELWYN GARDEN CITY, England and BOSTON, September 12, 2012 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, announces that its President, Dan Grau, will represent the Company at the 5th CNS Partnering and Deal-making conference [http://www.gtcbio.com/component/conference/?file=home&cn=5th+CNS+Partnering+and+Deal-making&cid=38 ] , which takes place at the Hilton San Francisco Financial District, San Francisco, CA (13-14 September)....
